文献速递颈动脉与弓上血管

双层支架颈动脉支架置入术的系统综述与Meta分析

Carotid Artery Stenting With Double-Layer Stent: A Systematic Review and Meta-Analysis.
PubMed 文献 · J Endovasc Ther · 2022-10-10

该系统综述与Meta分析纳入截至2022年1月1日的14项研究共1955例患者,评估双层支架(Roadsaver/Casper或CGuard)颈动脉支架置入术的30天卒中率。总体30天卒中率为1.4%(95%CI 0.9%-2.2%,I²=0%),症状性患者为1.9%(1.0%-3.6%),无症状患者为1.5%(0.8%-2.9%),支架类型间无显著差异(p=0.30)。30天支架闭塞率为0.8%(0.4%-1.8%)。

要点

  • 双层支架颈动脉支架置入术的30天总体卒中率为1.4%(95%CI 0.9%-2.2%)。
  • 症状性与无症状患者30天卒中率分别为1.9%和1.5%,无显著差异。
  • CGuard与Roadsaver/Casper支架的30天卒中率无显著差异(p=0.30)。

核心结论

  • 双层支架颈动脉支架置入术的30天总体卒中率低(1.4%),症状性与无症状患者结果相似,急性支架闭塞罕见(0.8%),需要进一步研究以减少无症状患者的发表偏倚。

研究设计与样本

  • 系统检索PubMed、Scopus和Cochrane Library(遵循PRISMA指南),纳入截至2022年1月1日关于双层支架(Roadsaver/Casper或CGuard)颈动脉支架置入术、队列至少20例患者的研究,排除串联病变或颈动脉完全闭塞患者,Meta分析在PROSPERO注册(CRD42022297512),共纳入14项研究1955例患者。

主要发现

  • 总体30天卒中率为1.4%(95%CI 0.9%-2.2%,I²=0%)。
  • CGuard组30天卒中率为0.8%(95%CI 0.4%-1.8%,I²=0%),Roadsaver/Casper组为1.5%(95%CI 0.7%-3.2%,I²=0%),两组差异无统计学意义(p=0.30)。
  • 无症状患者30天卒中率为1.5%(95%CI 0.8%-2.9%,I²=0%),症状性患者为1.9%(95%CI 1.0%-3.6%,I²=0%),调节因素无影响。
  • 30天双层支架闭塞率为0.8%(95%CI 0.4%-1.8%,I²=0%)。
  • 发表偏倚评估发现无症状人群存在不对称性。

临床怎么用

  • 作者指出,双层支架颈动脉支架置入术在症状性(1.9%)和无症状(1.5%)患者中均与低30天卒中率相关,支架类型(CGuard或Roadsaver/Casper)不影响30天卒中率。

局限性

  • 需要进一步研究以减少无症状患者的发表偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Carotid artery stenting (CAS) in the treatment of significant stenosis is a cause of stroke due to both plaque prolapse and cerebral embolization. New types of stents with a double-layer structure have been designed to minimize plaque prolapse and embolization; these double-layer stents (DLSs) should be able to reduce the stroke risk; however, definite data on their performance are scarce in the literature. METHODS: A systematic search was performed through PubMed, Scopus, and Cochrane Library, according to PRISMA guidelines; all studies on CAS with DLS (Roadsaver/Casper or CGuard) up to January 1, 2022, with a cohort of at least 20 patients were considered eligible. The present meta-analysis was approved and registered on PROSPERO register (CRD42022297512). Patients with tandem lesions or complete carotid occlusion were excluded from the study. The 30-day stroke rate after CAS was analyzed evaluating the preoperative symptomatic status and DLS occlusion. The estimated pooled rate of events was calculated by random effect model and moderators were evaluated. RESULTS: A total of 14 studies were included in the meta-analysis for a total of 1955 patients. The estimated overall (95% confidence interval [CI]) stroke rate was 1.4% (0.9%-2.2%, I2 = 0%), which was not influenced by the type of DLS used: CGuard 0.8% (0.4%-1.8%, I2 = 0%) versus Roadsaver/Casper 1.5% (0.7%-3.2%, I2 = 0%), p=0.30. The 30-day estimated stroke rate was 1.5% (0.8%-2.9%, I2 = 0%) in asymptomatic and 1.9% (1.0%-3.6%, I2 = 0%) in symptomatic patients, with no influence by moderators. The 30-day DLS occlusion rate was 0.8% (0.4%-1.8%, I2 = 0%). The publication bias assessment identified asymmetry in the asymptomatic populations. CONCLUSION: The overall 30-day stroke rate in CAS with DLS is low (1.4%), with similar results in symptomatic and asymptomatic patients. Acute occlusion of DLS is rare (0.8%). Further studies are necessary to reduce the publication bias for asymptomatic patients. CLINICAL IMPACT: CAS with DLS is associated to a low rate of 30-day stroke in both symptomatic (1.9%) and asymptomatic (1.5%) patients. The type of DLS (CGuard or Roadsaver/Casper) did not affect the 30-day stroke rate.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Pini R, Faggioli G, Paraskevas KI, et al. Carotid Artery Stenting With Double-Layer Stent: A Systematic Review and Meta-Analysis. J Endovasc Ther. 2022. PMID: 36214459. doi:10.1177/15266028221126940

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。